Bioprocess Engineering of Cells for Therapy

在过去的5年里，我们见证了细胞和基因疗法的重大进步，例如治愈了以前无法治愈的失明和癌症。这只是医学革命的第一步，这场革命是由数百项正在进行的针对其他癌症、糖尿病和心血管疾病的细胞疗法的临床试验推动的。这些新兴疗法的巨大前景伴随着巨大的挑战，其中许多是细胞培养过程工程领域的挑战。这项研究计划的长期目标是开发能够更安全、更经济地生产细胞治疗产品的技术。这对于确保许多有希望的新兴医疗保健技术真正广泛地为需要它们的患者提供是至关重要的。最终，更多地获得安全和负担得起的细胞培养产品将改善成千上万加拿大人的生活质量。不列颠哥伦比亚大学和加拿大多学科组织在这一领域的研究中处于领先地位。出口这些技术和知识应该会使世界各地的人民受益，并转化为加拿大人的巨大商业利益。

In the past 5 years, we have witnessed major cell and gene therapy advances, for example curing previously untreatable types of blindness and cancers. These are only the first of what should be a revolution in medicine, driven by hundreds of ongoing clinical trials of cellular therapies for other cancers, diabetes and cardiovascular diseases. The great promise of these emerging treatments comes with great challenges, many of those in the field of cell culture process engineering. The long-term goal of this research program is to develop technologies that will enable safer and more economical manufacture of cellular therapy products. This is essential to ensure that many promising emerging health care technologies actually become widely available to the patients who need them. Ultimately, increased access to safe and affordable cell culture products will improve the quality of many thousands of Canadian lives. UBC and Canadian multidisciplinary groups are among the leaders in this area of research. Exporting these technologies and knowledge should benefit populations around the world as well as translate into substantial commercial benefits for Canadians.